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We have measured by indirect ELISA the binding of neutralizing and non-neutralizing anti-lactate dehydrogenase-elevating
virus (LDV) polyclonal and monoclonal antibodies to synthetic peptides representing unmodified hydrophilic segments of LDV
proteins. Using this method a single neutralization epitope has been shown to be located in the very short (about 30 amino
acid long) ectodomain of the primary envelope glycoprotein, VP-3P, encoded by ORF 5. Although the neutralization epitopes
of neuropathogenic and non-neuropathogenic LDVs differ slightly in amino acid sequences, the neutralizing antibodies bind
strongly to the epitopes of both groups of viruses. However, the neutralization epitopes of neuropathogenic and non-
neuropathogenic LDVs are associated with different numbers of polylactosaminoglycan chains (1 and 3, respectively) which
may affect the binding of neutralizing antibodies to the virions of these LDVs. The ELISA using synthetic peptides containing
the neutralization epitope provides a novel, rapid, sensitive, and inexpensive method for quantitating LDV neutralizing
antibodies in infected mice. © 1998 Academic Press
Lactate dehydrogenase-elevating virus (LDV) is a
member of the Arteriviridae (Cavanagh, 1997). LDV nor-
mally establishes a lifelong persistent infection in its only
identified host, the mouse (Plagemann, 1996), which is
maintained by continuous rounds of cytocidal replication
in a subpopulation of macrophages in spite of humoral
and cellular anti-LDV immune responses (Plagemann,
1996; Plagemann et al., 1995). The infection is asymp-
tomatic, except for a 5-10 fold elevation in plasma lactate
dehydrogenase (LDH) activity which is invariably asso-
ciated with an LDV infection (Plagemann and Moennig,
1992; Plagemann, 1996). In addition to infecting macro-
phages, some isolates of LDV can cytocidally infect an-
terior horn neurons in certain mouse strains, such as
AKR and C58, and thus cause paralytic disease (age-
dependent poliomyelitis [ADPM]; Martinez, et al., 1980;
Murphy et al., 1983; 1987; Anderson et al., 1995b). How-
ever, infection of the central nervous system (CNS) by
these neuropathogenic LDVs is blocked by anti-LDV im-
mune responses (Harty and Plagemann, 1990; Anderson
et al., 1995a).
Recent experiments have shown that various original
isolates of LDV, such as LDV-PLA (Brinton-Darnell and
Plagemann, 1975) or LDV-RIL (Riley et al., 1960), consist
of at least two different non-neuropathogenic LDV qua-
sispecies, LDV-P and LDV-vx, whereas populations of the
original neuropathogenic LDV-C-BR (Martinez et al.,
1980) and LDV-VIR (Anderson et al., 1995a) were found to
contain neuropathogenic LDV quasispecies LDV-C and
LDV-v, respectively, in addition to non-neuropathogenic
LDV-vx and/or LDV-P (Chen et al., 1997; Chen and Plage-
mann, 1997). The different quasispecies have been iden-
tified and distinguished by sequence analyses of ORFs 2
and 5, and differential reverse-transcription (RT)- poly-
merase chain reaction (PCR) assays that are based on
sequence differences in ORF 2 and ORF 5 (Chen et al.,
1997; Chen and Plagemann, 1997). By repeated end point
dilutions in mice we have biologically cloned the two
neuropathogenic LDVs, LDV-C and LDV-v and the two
non-neuropathogenic LDVs, LDV-P and LDV-vx (Chen et
al., 1997, and unpublished data). These cloned LDV qua-
sispecies have allowed us to further explore phenotypic
differences between the non-neuropathogenic and neu-
ropathogenic LDVs and the molecular mechanisms re-
sponsible for these differences. The neuropathogenic
LDVs have been found to possess an impaired ability to
establish long-term persistent infections in either ADPM-
susceptible or non-susceptible mice (Chen et al., 1997).
For neuropathogenic LDVs, both the blockage of the
infection of the CNS by anti-LDV immune responses and
their impaired ability to establish a persistent infection
could be due to an increased susceptibility of these
LDVs to humoral immune responses of the host.
In the course of testing this hypothesis we have de-
termined that the neutralization epitope of LDV is located
on the very short ectodomain of the primary envelope
glycoprotein, VP-3P (encoded by ORF 5), using a novel
synthetic peptide ELISA. We also demonstrate that the
neutralization epitopes of the non-neuropathogenic and
1 To whom correspondence and reprint requests should be ad-
dressed.
VIROLOGY 242, 239–245 (1998)
ARTICLE NO. VY979014
0042-6822/98 $25.00
Copyright © 1998 by Academic Press
All rights of reproduction in any form reserved.
239
neuropathogenic LDVs are very similar and strongly
cross react.
RESULTS AND DISCUSSION
To identify the neutralization epitope(s) of LDV, we
directed our attention primarily to VP-3P, since previous
results from two laboratories showed that all anti-LDV
neutralizing MAbs that have been generated so far are
directed to VP-3P (Harty and Plagemann, 1988; Coutelier
et al., 1986; Coutelier and van Snick, 1988). Anti-VP-3P
antibodies are also the primary antibodies generated in
infected mice (Coutelier et al., 1986; Cafruny et al., 1986).
VP-3P is disulfide bonded, probably via its short ectodo-
main (about 30 amino acids long) to the ectodomain of
the non-glycosylated envelope protein, M/VP-2 (encoded
by ORF 6; Faaberg et al., 1995; Faaberg and Plagemann,
1995; see Fig. 1B). The membrane topography of VP-3P
suggested that its neutralization epitope(s) is located in
this ectodomain. To investigate this postulation we have
used indirect ELISA to measure the binding of polyclonal
anti-LDV antibodies (IMP), and also of various neutraliz-
ing and non-neutralizing MAbs, to a synthetic peptide
representing the complete VP-3P ectodomain of LDV-P
(ORF 5-P3; see Fig. 1A). Although virus neutralization
epitopes are generally non-contiguous three dimen-
sional structures, using a linear synthetic peptide
seemed justified in the case of LDV VP-3P, since its
processed ectodomain containing the postulated neu-
tralization epitope is very short and cross linkage to
M/VP-2 must impose certain structural constraints. We
also assessed the binding of the various antibodies to
synthetic peptides representing other hydrophilic seg-
ments of VP-3P and of other LDV-proteins (see Fig. 1A
and Materials and Methods).
The results in Fig. 2A show that the ORF 5-P3 peptide
representing the entire VP-3P ectodomain of LDV-P spe-
cifically bound antibodies from the plasma of FVB mice
that had been infected with LDV-PLA (consisting of non-
neuropathogenic LDV-P and LDV-vx) for 3 months. The
IMP did not significantly react with the peptides repre-
senting the N-terminal end of the VP-3P ectodomain
(ORF 5-P1) or a C-terminal segment of VP-3P (ORF 5-P2).
Furthermore, substitution of four amino acids in ORF
5-P3 (ORF 5-P4) resulted in almost complete loss of
reactivity with IMP. Antibodies generated in mice in-
fected with the neuropathogenic LDV-C or LDV-v also
reacted with the LDV-P specific ORF 5-P3 (Fig. 2B). The
results indicate that IMP from both LDV-PLA and LDV-C/v
infected mice contained antibodies that specifically re-
acted with the ectodomain of VP-3P of LDV-P.
FIG. 1. Amino acid sequences of the ORF 5 protein (VP-3P) of LDV-P and of ORF 5 specific peptides P1–P7 (A) and a model for the topography of
VP-3P and M/VP-2 of LDV-P in the virion envelope (B). (A) The signal peptide and the putative transmembrane segments are overlined and the
potential N-glycosylation sites in the ectodomain are indicated by  (Palmer et al., 1995). The synthetic peptides to the ORF 5 protein are shown in
boxed regions. ORF 5-P1, P2, and P3 are specific for LDV-P. ORF 5-P4 is a mutated version of ORF 5-P3 with four amino acid substitutions. ORF 5-P5
represents the VP-3P ectodomain of LDV-C (Godeny et al., 1993) and LDV-v (unpublished data). ORF 5-P6 contains combined amino acid substitutions
found in the ectodomains of VP-3P of LDV-vx and LDV-a, another non-neuropathogenic LDV isolate provided by W. Murphy (unpublished data). ORF
5-P7 is a truncated form of LDV-P ORF 5-P3 with five amino acids removed from the N-terminus and four from the C-terminus. (B) C designates the
polylactosaminoglycan chains on the processed ectodomain of VP-3P of the non-neuropathogenic LDVs and the N- and C-terminal ends of the
proteins are indicated. The -S-S- indicates the postulated position of the disulfide bond that bridges the ectodomains of VP-3P and M/VP-2 (Faaberg
et al., 1995; Faaberg and Plagemann, 1995).
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That the ectodomain of VP-3P contains a neutralization
epitope was unequivocally proven by the specific bind-
ing of neutralizing MAbs to the peptide ORF 5-P3. The
neutralizing MAb 159-19 (see Table 1) strongly bound to
ORF 5-P3 representing the ectodomain of LDV-P VP-3P,
but not to ORF 5-P1 or ORF 5-P2 (Fig. 3). As with IMP, the
four amino acid substitutions in ORF 5-P3 (ORF 5-P4)
abolished the binding of MAb 159-19. There was also no
interaction of MAb 159-19 with the synthetic peptides
derived from segments of the nucleocapsid protein (N/
VP-1), the non-glycosylated envelope protein (M/VP-2) or
the ORF 3 protein (data not shown). Furthermore, a non-
neutralizing MAb to VP-3P (159-4) reacted only very
weakly with ORF 5-P3 and not with any of the other ORF
5 peptides (Fig. 3 and data not shown). Thus, the reaction
of the neutralizing MAb 159-19 with the VP-3P ectodo-
main (ORF 5-P3) was highly specific. All other neutraliz-
ing MAbs that have been shown in competitive ELISA
analyses to react with the same epitope as MAb 159-19,
namely 159-7, 159-12, 159-16 and 159-18 (Harty and
Plagemann, 1988; see Table 1), exhibited the same high
specificity for ORF 5-P3 (data not shown). In fact, ascites
fluids of some of these MAbs possessed titers for ORF
5-P3 of over 100,000 (see later, Fig. 5). Similarly, a num-
ber of neutralizing MAbs to VP-3P generated in another
laboratory (E7, H12, H9 and A4; Coutelier and van Snick,
1988) were specific for ORF 5-P3 (Fig. 4). In contrast,
none of the peptides reacted significantly with four other
non-neutralizing MAbs to VP-3P, namely 159-3, 159-5,
159-13 and 159-14 (Table 1) that recognize at least two
different epitopes on VP-3P (Harty and Plagemann, 1988;
data not shown), or with MAbs to N/VP-1 (C350201.7) or
FIG. 2. ELISA measurements of the binding of NMP and IMP from LDV-PLA infected mice to different peptides of the ORF 5 protein (A) and of IMP
from LDV-C and LDV-v infected mice to ORF 5-P3 (B). (A) ORF 5-P1–P4 are synthetic peptides representing different hydrophilic segments of the ORF
5 protein of LDV-P (see Fig. 1A). IMP was collected from a group of 3-month LDV-PLA infected mice. NMP was collected from mice that had not been
exposed to LDV. ELISA was conducted as described under Materials and Methods. (B) IMP was collected from two or three FVB mice at the indicated
times p.i. with cloned LDV-C or LDV-v.
TABLE 1
Characteristics of Anti-LDV MAbs
MAb Isotype Specificity Neutralizationa
159-7b IgG2a VP-3P 1
159-12 IgG2b VP-3P 1
159-16 IgG2b VP-3P 1
159-18 IgG2a VP-3P 1
159-19 IgG1 VP-3P 1
159-3 IgG1 VP-3P 2
159-4 IgG1 VP-3P 2
159-5 IgG1 VP-3P 2
159-13 IgG1 VP-3P 2
159-14 IgG1 VP-3P 2
B6503-E7c IgG2a VP-3P 1
C3904-H12c IgG3 VP-3P 1
B6505-H9c IgG2a VP-3P 1
B6501-A4c IgG2a VP-3P 1
F2d IgG1 ORF 3 protein 2
C350201.7c IgG1 N/VP-1 2
a In vitro neutralization of LDV-PLA, LDV-RIL, LDV-P, LDV-C, LDV-v, or
all of them (Harty and Plagemann, 1988; Coutelier and van Snick, 1988;
and unpublished data). In vitro neutralization of LDV infectivity was
measured as described previously (Coutelier et al., 1986; Cafruny et al.,
1986; Plagemann et al., 1992). In brief, samples of LDV were incubated
with NMP or anti-LDV antibodies in vitro and residual infectivity was
measured by an end point dilution assay in mice.
b The battery of MAbs 159 was generated to formalin-inactivated
LDV-PLA (Harty and Plagemann, 1988).
c These MAbs were generated with spleen cells from LDV-RIL in-
fected mice, except for C350201.7 which was generated to isolated
nucleocapsids (Coutelier et al., 1986; Coutelier and van Snick, 1988).
They were provided by J.-P. Coutelier.
d MAb F2 was generated with spleen cells from LDV-PLA infected
mice (unpublished data).
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to the nonstructural glycoprotein encoded by ORF 3 (F2;
Fig. 4).
To further investigate the nature of the neutralization
epitope, we have assayed the MAb reactivity of a peptide
that represented the ectodomain of the neuropathogenic
LDV-C and LDV-v (ORF 5-P5; see Fig. 1A). We also tested
a peptide, ORF 5-P6, that differed from the LDV-P specific
ORF 5-P3 by three amino acids that are present in the
VP-3P ectodomains of LDV-vx, of LDV-a (another non-
neuropathogenic LDV isolate) or both. Both peptides
bound neutralizing MAb 159-18 to a similar extent as
ORF 5-P3 (Fig. 5), although the reactivity of the LDV-C/v
specific ORF 5-P5 was slightly lower than those of the
LDV-P and LDV-vx/a specific peptides (ORF 5-P3 and
ORF 5-P6, respectively). The results clearly indicate that
the neutralization epitopes of the five LDV quasispecies
FIG. 3. ELISA measurements of the binding of neutralizing (159-19) and non-neutralizing (159-4) anti-VP-3P MAbs to peptides ORF 5-P1-P4. MAbs
159-19 and 159-4 were generated to formalin-inactivated LDV-PLA (Harty and Plagemann, 1988; see Table 1) and used in ascites fluid prepared in
BALB/c mice. ORF 5-P1–P4 represent different segments in the VP-3P of LDV-P (see Fig. 1A). ELISA was performed as described under Materials and
Methods.
FIG. 4. ELISA measurements of the binding of additional anti-VP-3P neutralizing MAbs (B6503-E7, C3904-H12, B6505-H9, and B6501-A4), an
anti-ORF 3 protein MAb (F2) and an anti-N/VP-1 MAb (C350201.7) to ORF 5-P3 and P4. The origins and properties of the MAbs are described in Table
1. ORF 5-P3 represents the VP-3P ectodomain of LDV-P, whereas ORF 5-P4 is a mutated ORF 5-P3 with four amino acid substitutions (see Fig. 1A).
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are very similar with respect to the binding of neutraliz-
ing antibodies. In order to more clearly define the neu-
tralization epitope in the VP-3P ectodomain, we mea-
sured the binding of the MAbs to a truncated version of
ORF 5-P3 (ORF 5-P7) in which five amino acids from the
N-terminus and four amino acids from the C-terminus
were omitted (see Fig. 1A). This peptide specifically
bound neutralizing MAb 159-18, but less efficiently than
did ORF 5-P3, P5 or P6 (Fig. 5). The results indicate that
the truncated peptide contains the major part of the
neutralization epitope, but may be missing amino acids
required for optimal antibody binding. If this is the case,
the missing amino acids may be located at the C-termi-
nal end since amino acid substitutions in the N-terminal
region did not seem to affect antibody binding efficiency.
However, I43, Y44 or both seem critical for neutralizing
antibody binding, since substitution by T and S, respec-
tively, abolished all binding activity. In contrast, the same
amino acid substitutions at residues 45 and 46, as in the
LDV-C/v epitope (see Fig. 1A), affected binding only min-
imally (Fig. 5). That the neutralization epitope is located
in the ectodomain between amino acids 37 and 60 is
also indicated by our sequence analysis of ORF 5 from a
neutralization escape variant previously isolated from
LDV-PLA (Harty and Plagemann, 1988). The variant was
completely resistant to in vitro neutralization by MAbs
159-12 and 159-18 (Harty and Plagemann, 1988). ORF 5 of
this variant was found to differ from that of LDV-P by only
two nucleotides (data not shown) resulting in one amino
acid substitution in its VP-3P, T393 A, which was located
in the neutralization epitope and thus probably respon-
sible for the increased resistance to antibody neutraliza-
tion.
In summary, we have demonstrated, by indirect ELISA
using synthetic peptides, that the neutralization epitope
of LDV is located on the short ectodomain of VP-3P. The
ELISA using a synthetic peptide containing the neutral-
ization epitope provides a novel method for measuring
LDV neutralizing antibodies which is highly specific,
rapid, inexpensive and much more sensitive than the
assay based on the in vitro neutralization of infectious
virions. Also, it does not require mice for quantitation of
non-neutralized virions. With this method we have dem-
onstrated that MAbs to the non-neuropathogenic LDVs
bind about equally to the epitopes of the neuropatho-
genic and non-neuropathogenic LDV quasispecies (Ta-
ble 1 and Fig. 5). Vice versa, antibodies generated in
neuropathogenic LDV-C/v infected mice bind efficiently
to the neutralization epitope of non-neuropathogenic
LDV-P (Fig. 2B). The results indicate strong cross-reac-
tions between all LDV quasispecies identified so far and
that the amino acid differences in their neutralization
epitopes do not greatly affect the binding of neutralizing
antibodies. In contrast, a slight shifting in the position of
four amino acids in the neutralization epitope specific for
LDV-C/v (V33, D36, T45, S46 to V32, D35, T43, S44), almost
completely abolished antibody binding to the epitope
(Figs. 2A, 3, and 4). Since the N-terminal amino acids did
not seem to affect antibody binding efficiency, the I43, Y44,
FIG. 5. ELISA measurements of the binding of neutralizing MAb 159-18 and non-neutralizing MAb 159-3 (see Table 1) to peptides representing the
VP-3P ectodomain of LDV-P (ORF 5-P3), LDV-C/v (ORF 5-P5), and LDV-vx/a (ORF 5-P6) and to a truncated form of LDV-P ORF 5-P3 (ORF 5-P7).
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or both must be important for recognition by neutralizing
antibodies.
It is unusual that the LDV neutralization epitope ap-
pears to be a linear peptide, since antibodies tend to
recognize conformational structures that are often non-
contiguous. The linear nature of the epitope may be due
to the shortness of the processed ectodomain of VP-3P
and its disulfide bonding to the even shorter (about 11
amino acid long) ectodomain of M/VP-2 (see Fig. 1A).
This structure may also limit the number of potential
epitopes on the virion surface. Our results also indicate
that the LDV neutralization epitope is an unmodified
peptide, whereas in VP-3P of virions it is associated with
three or one polylactosaminoglycan chain(s) for the non-
neuropathogenic and neuropathogenic LDVs, respec-
tively (see Fig. 1A). It seems possible therefore that the
generation of neutralizing antibodies by non-neuropatho-
genic LDVs depends on the removal of one or more of
the polylactosaminoglycan chains leading to exposure of
the epitope. This suggestion is supported by our recent
finding that neutralizing antibodies are generated more
rapidly in neuropathogenic than non-neuropathogenic
LDV infected mice (unpublished data).
The finding that the neutralizing epitopes of neuro-
pathogenic and non-neuropathogenic LDVs are serolog-
ically very similar is important in relation to the impaired
ability of the neuropathogenic LDVs to establish a high
viremic persistent infection (Chen et al., 1997; and un-
published data). Recent studies in progress suggest that
this impaired ability of the neuropathogenic LDVs to
establish a persistent infection is partly due to increased
immunogenicity but more importantly to an increased
sensitivity to neutralization by antibodies (unpublished
data). The finding that the neutralization epitopes of the
neuropathogenic and non-neuropathogenic LDVs are
closely related and cross react, suggests that differ-
ences in sensitivity to antibody neutralization are most
likely not due to amino acid differences in their neutral-
ization epitopes per se but rather to differences in the
number of polylactosaminoglycan chains associated
with their neutralization epitopes (see Fig. 1A).
The presence of neutralization epitope(s) on the
ectodomain of the primary envelope glycoprotein en-
coded by ORF 5 may be a common characteristic of
arteriviruses. In the case of equine arteritis virus (EAV),
three overlapping neutralization epitopes are also lo-
cated in the ectodomain of the primary envelope glyco-
protein (GL) just upstream of the first transmembrane
segment (Balasuriya et al., 1995). However, the ectodo-
main of the EAV GL protein is much larger than that of
VP-3P of LDV. On the other hand, the ORF 5 protein of the
arterivirus porcine reproductive and respiratory syn-
drome virus is very similar to VP-3P of LDV in size,
structure and amino acid sequence (about 50% amino
acid identity; Plagemann, 1996). The protein also pos-
sesses neutralization epitopes but their location in the
protein have not been identified (Pirzadeh and Dea,
1997).
MATERIALS AND METHODS
LDV
LDV concentrations were measured by an end point
dilution assay in mice which is based on the plasma LDH
elevation characteristic for LDV infected mice (Plage-
mann et al., 1963). Virus titers were expressed as 50%
infectious units (ID50). Stocks of LDVs consisted of
plasma harvested from groups of mice at 1 day p.i. and
contained 109 to 1010 ID50/ml. For long-term infections
mice were infected by intraperitoneal injection of about
106 ID50. To obtain plasma the mice were bled by the
orbital method using heparinized Natelson blood collect-
ing tubes (Chen and Plagemann, 1997).
Anti-LDV antibodies
Immune mouse plasma (IMP), containing polyclonal
anti-LDV antibodies, was pooled from mice which had
been infected with LDV for varying lengths of time (Caf-
runy et al., 1986). The anti-LDV antibodies are primarily of
IgG2a, IgG2b and IgG3 isotype and directed to the pri-
mary envelope glycoprotein (VP-3P), the nucleocapsid
protein (N/VP-1) and the ORF 3 protein (Cafruny et al.,
1986; Coutelier et al., 1986; Faaberg and Plagemann,
1997). IMP was freed of infectious LDV by three consec-
utive extractions with ethyl ether (Cafruny et al., 1986).
The anti-LDV monoclonal antibodies (MAbs) used in the
present study and their properties are listed in Table 1.
They were used in ascites fluid or after purification by
protein A chromatography in the case of B6505-H9 and
B6501-A4 (Coutelier and van Snick, 1988).
Measurement by ELISA of anti-LDV antibody binding
to LDV peptides
Synthetic peptides representing various hydrophilic
segments of LDV proteins were provided by the Biotech-
nology Core Facility at the Centers for Disease Control
and Prevention. The ORF 5 protein (VP-3P) specific pep-
tides (P1-P7) are outlined in Fig. 1A. Peptides represent-
ing segments of other LDV-P proteins were as follows:
ORF 3 protein (a nonstructural glycoprotein; Faaberg and
Plagemann, 1997), P1 5 L32 2 G40, P2 5 F68 2 S78; ORF
6 protein (the non-glycosylated envelope protein, M/VP-
2), P1 5 A107 2 G117, P2 5 V151 2 G161; ORF 7 protein
(nucleocapsid protein, N/VP-1), P1 5 S2 2 G13, P2 5 N32
2 P43 (Palmer et al., 1995; GenBank accession number
U15146; the letters with superscript designations repre-
sent the starting and ending amino acids of each pep-
tide).
Flat bottom, 96-well microtiter plates (Becton Dickin-
son, Lincoln Park, NJ) were used for indirect ELISA. The
wells were coated overnight with the various synthetic
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peptides in 25 mM carbonate-bicarbonate buffer, pH 9.6
(2 mg/well). The wells were washed five times with PBS
containing 0.05% (v/v) Tween 20 (PBS-Tween) and then
incubated with 100 ml of PBS-Tween containing 1% (w/v)
bovine serum albumin (blocking solution) for 2 h at 37°C.
The wells were again washed five times with PBS-Tween
and then incubated with 100 ml of 2 fold serial dilutions
made in blocking solution of either normal mouse
plasma (NMP), IMP, or ascites fluid containing an anti-
LDV MAb for 2 h at 37°C. After another set of washes
with PBS-Tween, the wells were incubated with 100 ml of
a 1:1000 dilution of alkaline phosphatase-conjugated
goat anti-mouse IgG (Sigma, St. Louis, MO) for 1 h at
37°C. After five washes with PBS-Tween and two with
Tris-HCl-buffered saline (pH 7.4), the wells were incu-
bated with alkaline phosphatase substrate (Sigma) for
about 30 min in the dark. The absorbency of the reaction
solution was measured at 405 nm (A405) with an auto-
mated microplate reader.
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